NS Healthcare is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
Home » pressreleases » Haselmeier announces the German launch of the BerliPen® areo 3 through Berlin-Chemie

a leading developer and manufacturer of innovative self-injection devices

Press
Release

Haselmeier announces the German launch of the BerliPen® areo 3 through Berlin-Chemie

Berlin-Chemie launched the new BerliPen® areo 3 on the German market in April 2016. Based on Haselmeier’s i-pen platform, the BerliPen® areo 3 is a 300 unit insulin pen for use with six different insulins (Berlinsulin H and Liprolog types) in the treatment of type 1 and 2 diabetes.

Key features of this third-generation BerliPen® are an optimized dose indicator, innovative low-friction mechanism for smooth injection release in addition to an enhanced feeling of safety by means of audible and tactile dose settings. The BerliPen® areo 3 comes onto the market with five different metallic colours – black, blue, green, red and yellow.

"The declared aim of Haselmeier was to enable the product launch of our valuable partner Berlin- Chemie, the BerliPen® areo 3 project was brought to a successful conclusion with the issuance of the declaration of conformity. Ultimately, we were successful in implementing this by joining forces; setting a milestone both for Haselmeier and Berlin-Chemie", says Tobias Alberstetter, project manager of Haselmeier GmbH.

Contact a leading developer and manufacturer of innovative self-injection devices

a leading developer and manufacturer of innovative self-injection devices